Back to top

Pyxis Oncology initiated with an Overweight at Wells Fargo

Wells Fargo initiated coverage of Pyxis Oncology (PYXS) with an Overweight rating and $12 price target The firm says dose capping likely addresses ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Pyxis Oncology, Inc. (PYXS)